Access the world's leading financial data and tools

Subscribe for $2
Overview
Profile

Legend Biotech stock

LEGN
US52490G1022
A2P5AH

Price

39.69
Today +/-
-0.32
Today %
-0.86 %
P

Legend Biotech stock price

%
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the Legend Biotech stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the Legend Biotech stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the Legend Biotech stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze Legend Biotech's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

Legend Biotech Stock Price History

DateLegend Biotech Price
11/8/202439.69 undefined
11/8/202440.03 undefined
11/7/202440.95 undefined
11/6/202441.39 undefined
11/5/202444.62 undefined
11/4/202443.61 undefined
11/1/202444.36 undefined
10/31/202445.02 undefined
10/30/202444.27 undefined
10/29/202445.46 undefined
10/28/202445.30 undefined
10/25/202444.74 undefined
10/24/202444.06 undefined
10/23/202443.95 undefined
10/22/202445.04 undefined
10/21/202443.45 undefined
10/18/202442.87 undefined
10/17/202443.09 undefined
10/16/202444.02 undefined
10/15/202444.91 undefined
10/14/202449.68 undefined
10/11/202450.00 undefined

Legend Biotech Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Legend Biotech, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Legend Biotech from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Legend Biotech’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Legend Biotech. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Legend Biotech’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Legend Biotech’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Legend Biotech’s growth potential.

Legend Biotech Revenue, EBIT and net profit per share

DateLegend Biotech RevenueLegend Biotech EBITLegend Biotech Net Income
2029e3.25 B undefined0 undefined1.17 B undefined
2028e2.9 B undefined1.12 B undefined1.06 B undefined
2027e2.32 B undefined678.35 M undefined683.67 M undefined
2026e1.66 B undefined190.91 M undefined189.44 M undefined
2025e1.06 B undefined-178.31 M undefined-250.32 M undefined
2024e598.91 M undefined-338.83 M undefined-401.48 M undefined
2023285.14 M undefined-527.97 M undefined-518.25 M undefined
2022117 M undefined-458.1 M undefined-446.3 M undefined
202168.8 M undefined-394 M undefined-403.6 M undefined
202075 M undefined-309.8 M undefined-266.4 M undefined
201960 M undefined-134.3 M undefined-101.6 M undefined
201849.1 M undefined-15.4 M undefined-2.8 M undefined
201723.6 M undefined13.8 M undefined9.4 M undefined

Legend Biotech Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (B)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (M)EBIT (B)EBIT MARGIN (%)NET INCOME (B)NET INCOME GROWTH (%)SHARES (M)DOCUMENTS
20172018201920202021202220232024e2025e2026e2027e2028e2029e
0.020.050.060.080.070.120.290.61.061.662.322.93.25
-113.0422.4525.00-9.3372.06143.59109.8277.4256.6439.6524.8212.15
-----43.5949.12------
0000051140000000
0.01-0.02-0.13-0.31-0.39-0.46-0.53-0.34-0.180.190.681.120
56.52-30.61-223.33-412.00-579.41-391.45-184.91-56.52-16.7811.4329.2138.76-
0.01-0-0.1-0.27-0.4-0.45-0.52-0.4-0.250.190.681.061.17
--122.224,950.00163.3751.5010.6716.14-22.59-37.66-175.60261.3854.6110.98
258.7258.7200236.3281.7318.1352.17000000
-------------
Details

Keystats

ⓘ

Revenue and Growth

The Legend Biotech Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Legend Biotech is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (B)RECEIVABLES (M)OTHER REC. (M)INVENTORIES (M)OTHER CURRENT LIAB. (M)CURRENT ASSETS (B)TANGIBLE ASSETS (M)LONG-T. INVEST. (M)LONG-T. REC. (M)INTANGIBLE ASSETS (M)GOODWILL (M)OTHER NON-CURRENT ASSETS (M)NON-CURRENT ASSETS (M)TOTAL ASSETS (B)LIABILITIESCOMMON STOCK (k)ADDITIONAL PAID-IN CAPITAL (M)RETAINED EARNINGS (B)OTHER EQUITY (M)UNREAL. GAINS/LOSSES (M)EQUITY (B)LIABILITIES (M)PROVISIONS (M)OTHER SHORT-TERM LIAB. (M)SHORT-TERM DEBTS (k)LONG-TERM DEBT PORTION (M)SHORT-TERM REC. (M)LONG-T. LIAB. (M)DEFERRED TAXES (M)OTHER LIAB. (M)LONG-T. LIABILITIES (M)DEBT (M)TOTAL CAPITAL (B)
2017201820192020202120222023
             
00.220.160.510.881.031.31
22826.2307550.40.1100.04
0007.57.945.457.02
01.11.21.81.710.419.43
0.883.221.73.55.916.312.23
0.230.330.210.590.951.11.5
2.931.973111.9140.8160.8189.23
0000000
01.20.70.22.20.90.74
000.52.94.73.44.06
0000000
4.968.96.413.22266.8156.79
7.810280.6128.2169.7231.9350.81
0.240.430.290.721.121.331.85
             
00000036
0000000
0.010.010.150.60.770.741.25
0000000
0000000
0.010.010.150.60.770.741.25
4.37.680.54.9732.9152.96
7.933.9070.5100.6149.3102.44
39.9117.312.838.4120.7112.190.65
000300000
0.10.411.50.93.63.18
52.2159.294.3115.6229.2297.9349.22
0.23.95.11.9122.1281325.5
00424.2000
174.2257.302.62.37.955.32
174.4261.247.18.7124.4288.9380.82
226.6420.4141.4124.3353.6586.8730.04
0.240.430.290.721.121.331.98
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of Legend Biotech provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand Legend Biotech's financial health and stability.

Assets

Legend Biotech's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that Legend Biotech must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of Legend Biotech after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into Legend Biotech's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M)DEPRECIATION (M)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (M)NON-CASH ITEM (M)PAID INTEREST (k)PAID TAXES (M)NET CASH FLOW FROM OPERATING ACTIVITIES (M)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (M)CASH FLOW FROM OTHER INVESTING ACTIVITIES (M)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (M)NET CHANGE IN EQUITY (M)CASH FLOW FROM FINANCING ACTIVITIES (M)CASH FLOW FROM OTHER FINANCING ACTIVITIES ()TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (M)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
2017201820192020202120222023
13-1-130-307-386-445-520
0149131820
0000000
-1632045-11142201-25
0-12-1905259179
0000001,000
0015-70-30
-2307-83-223-198-201-393
0-21-39-49-47-22-22
0-102-58-24-195-7792
0-81-1925-147-54115
0000000
1214-2-1-2-3
100624628380795
3214618626378791
----2.00---
0000000
0208-12637223397491
-3.3286.7-122.3-272.8-245.6-223.6-416
0000000

Legend Biotech stock margins

The Legend Biotech margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Legend Biotech. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Legend Biotech.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Legend Biotech's sales revenue. A higher gross margin percentage indicates that the Legend Biotech retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Legend Biotech's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Legend Biotech's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Legend Biotech's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Legend Biotech. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Legend Biotech's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Legend Biotech Margin History

Legend Biotech Gross marginLegend Biotech Profit marginLegend Biotech EBIT marginLegend Biotech Profit margin
2029e49.42 %0 %36.1 %
2028e49.42 %38.75 %36.47 %
2027e49.42 %29.23 %29.46 %
2026e49.42 %11.49 %11.4 %
2025e49.42 %-16.81 %-23.59 %
2024e49.42 %-56.57 %-67.03 %
202349.42 %-185.16 %-181.75 %
202244.1 %-391.54 %-381.45 %
202149.42 %-572.67 %-586.63 %
202049.42 %-413.07 %-355.2 %
201949.42 %-223.83 %-169.33 %
201849.42 %-31.36 %-5.7 %
201749.42 %58.47 %39.83 %

Legend Biotech Stock Sales Revenue, EBIT, Earnings per Share

The Legend Biotech earnings per share therefore indicates how much revenue Legend Biotech has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Legend Biotech earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Legend Biotech's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Legend Biotech’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Legend Biotech's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Legend Biotech Revenue, EBIT and net profit per share

DateLegend Biotech Sales per ShareLegend Biotech EBIT per shareLegend Biotech Earnings per Share
2029e8.81 undefined0 undefined3.18 undefined
2028e7.86 undefined0 undefined2.87 undefined
2027e6.3 undefined0 undefined1.85 undefined
2026e4.51 undefined0 undefined0.51 undefined
2025e2.88 undefined0 undefined-0.68 undefined
2024e1.62 undefined0 undefined-1.09 undefined
20230.81 undefined-1.5 undefined-1.47 undefined
20220.37 undefined-1.44 undefined-1.4 undefined
20210.24 undefined-1.4 undefined-1.43 undefined
20200.32 undefined-1.31 undefined-1.13 undefined
20190.3 undefined-0.67 undefined-0.51 undefined
20180.19 undefined-0.06 undefined-0.01 undefined
20170.09 undefined0.05 undefined0.04 undefined

Legend Biotech business model

Legend Biotech Corp is a leading biopharmaceutical company specializing in the discovery and development of innovative cell therapies for the treatment of serious diseases such as cancer. The company was founded in 2015 as a subsidiary of Genscript Biotech Corp and is headquartered in Somerset, New Jersey, USA. Additionally, the company also operates locations in China and Europe. Legend Biotech is one of the most popular companies on Eulerpool.com.

Legend Biotech SWOT Analysis

Strengths

Legend Biotech Corp possesses several key strengths that contribute to its success in the market. Notable strengths include:

  • Strong research and development capabilities: Legend Biotech Corp has a highly skilled R&D team that continues to drive innovation and develop cutting-edge biotechnology products.
  • Robust pipeline: The company has a diverse and promising pipeline of potential biopharmaceutical products, enabling potential future growth.
  • Strategic partnerships: Legend Biotech Corp has established strategic collaborations with reputable industry players, allowing access to additional resources, expertise, and distribution channels.
  • Strong financial position: The company has a solid financial foundation, providing stability and resources for ongoing operations and investment in future growth.

Weaknesses

Despite its strengths, Legend Biotech Corp also faces certain weaknesses that could hinder its growth and performance. These weaknesses include:

  • Limited global market presence: The company's market reach is relatively limited, primarily focused on specific regions and markets, which may impact its ability to capture a broader customer base.
  • Dependency on key products: A significant portion of Legend Biotech Corp's revenue is heavily reliant on a few key products, creating susceptibility to market fluctuations or the success of these specific products.
  • Regulatory challenges: The biotechnology industry faces rigorous regulations, and compliance with these regulations can be time-consuming and costly, potentially affecting product development timelines.

Opportunities

Legend Biotech Corp can leverage several opportunities to maximize its market potential and expand its operations. Key opportunities include:

  • Increasing demand for biopharmaceuticals: The global demand for biologic drugs continues to rise, presenting a significant growth opportunity for Legend Biotech Corp to capture market share.
  • Emerging markets: Expanding into emerging markets with growing healthcare systems can provide the company with access to a broader customer base and untapped revenue streams.
  • Technological advancements: The rapid advancement of technology in biotechnology can open up new possibilities for Legend Biotech Corp in terms of product development, efficiency, and cost-effectiveness.

Threats

Legend Biotech Corp also faces certain threats that pose challenges to its operations and market position. These threats include:

  • Intense competition: The biopharmaceutical industry is highly competitive, with numerous established players and new entrants, intensifying competition for market share and resources.
  • Patent expirations: The expiration of patents for certain products may lead to increased competition from generics and impact the company's market share and profitability.
  • Economic fluctuations: Economic downturns or instability may lead to reduced healthcare spending, which could affect the demand for Legend Biotech Corp's products.

Legend Biotech Revenue by Region

  • 3 years

  • Max

Details

Revenue by Segment

ⓘ

Overview of Revenue by Region

The chart shows revenues by region and provides a clear comparison of regional revenue distribution. Each region is clearly marked to illustrate the differences.

Interpretation and Usage

The diagram helps to identify the regions with the highest revenue and to make targeted decisions for regional expansion or investments. It supports the analysis of market potentials and strategic priorities.

Investment Strategy

An investment strategy focused on regions concentrates on the deliberate capital allocation in different markets to optimally use regional growth opportunities. It takes into account market conditions and regional risk factors.

Legend Biotech Revenue by Segment

DateChinaNorth AmericaOther CountriesUnited States of America
2022328,000 USD-75,000 USD116.7 M USD
20213.42 M USD--86.4 M USD
2020-75.68 M USD--

Legend Biotech Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

Legend Biotech historical P/E ratio, EBIT multiple, and P/S ratio

Legend Biotech shares outstanding

The number of shares was Legend Biotech in 2023 — This indicates how many shares 352.165 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Legend Biotech earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Legend Biotech's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Legend Biotech’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Legend Biotech's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

The World’s Best Investors Are On Eulerpool

Unfortunately, there are currently no price targets and forecasts available for Legend Biotech.

Legend Biotech latest earnings and earnings surprises

DateEPS EstimateEPS ActualQuarterly report
6/30/2024-0.39 -0.1  (74.29 %)2024 Q2
3/31/2024-0.35 -0.32  (8.88 %)2024 Q1
12/31/2023-0.85 -0.8  (5.5 %)2023 Q4
9/30/2023-0.69 -0.34  (50.8 %)2023 Q3
6/30/2023-0.61 -1.14  (-86.27 %)2023 Q2
3/31/2023-0.8 -0.68  (14.53 %)2023 Q1
6/30/2022-0.43 -1.24  (-188.71 %)2022 Q2
3/31/2022-0.47 -0.26  (44.59 %)2022 Q1
12/31/2021-0.42 -0.3  (28.26 %)2021 Q4
9/30/2021-0.36 -0.43  (-18.75 %)2021 Q3
1
2

Eulerpool ESG Scorecard© for the Legend Biotech stock

Eulerpool World ESG Rating (EESG©)

38/ 100

🌱 Environment

41

👫 Social

40

🏛️ Governance

33

Environment

Scope 1 - Direct Emissions
Scope 2 - Indirect emissions from purchased energy
Scope 3 - Indirect emissions within the value chain
Total CO₂ emissions
CO₂ reduction strategy
Coal energy
Nuclear power
Animal experiments
Fur & Leather
Pesticides
Palm Oil
Tobacco
Genetically modified organisms
Climate concept
Sustainable forestry
Recycling regulations
Environmentally friendly packaging
Hazardous substances
Fuel consumption and efficiency
Water consumption and efficiency

Social

Percentage of female employees
Percentage of women in management
Percentage of Asian employees
Share of Asian management
Percentage of Hispanic/Latino employees
Hispano/Latino Management share
Percentage of Black employees
Black Management Share
Percentage of white employees
White Management Share
Adult content
Alcohol
Weapons
Firearms
Gambling
Military contracts
Human rights concept
Privacy concept
Occupational health and safety
Catholic

Governance (Corporate Governance)

Environmental reporting
Stakeholder Engagement
Call Back Policies
Antitrust law

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

Legend Biotech shareholders

%
Name
Stocks
Change
Date
4.34783 % Fidelity Management & Research Company LLC16,025,2351,110,6196/30/2024
3.11643 % T. Rowe Price Associates, Inc.11,486,539540,1286/30/2024
2.03672 % RA Capital Management, LP7,506,934645,8376/30/2024
1.80056 % HHLR Advisors, Ltd.6,636,496651,9466/30/2024
1.29476 % Westfield Capital Management Company, L.P.4,772,2092,532,4356/30/2024
0.93699 % BlackRock Institutional Trust Company, N.A.3,453,547321,2696/30/2024
0.76221 % Wellington Management Company, LLP2,809,368194,9456/30/2024
0.64004 % Janus Henderson Investors2,359,056345,0446/30/2024
0.61045 % Genscript Biotech Corp2,250,000012/31/2023
0.60301 % Capital Research Global Investors2,222,56662,7329/30/2024
1
2
3
4
5
...
10

Most common questions regarding Legend Biotech

What values and corporate philosophy does Legend Biotech represent?

Legend Biotech Corp is a leading biopharmaceutical company that values innovation, integrity, and a patient-centric approach. With a strong corporate philosophy focused on advancing novel cell therapies, Legend Biotech Corp strives to improve the lives of patients around the world. The company is committed to developing cutting-edge treatments for oncology and autoimmune diseases, utilizing its expertise in gene and cell therapies. With a dedication to scientific excellence and a patient-first mindset, Legend Biotech Corp continues to push the boundaries of medical innovation and deliver transformative therapies to those in need.

In which countries and regions is Legend Biotech primarily present?

Legend Biotech Corp is primarily present in multiple countries and regions. With its headquarters in Somerset, New Jersey, the company has an extensive global presence. It operates in key markets such as the United States, China, and Europe. Legend Biotech Corp has established strategic collaborations and partnerships to extend its reach and leverage market opportunities. By expanding its operations internationally, the company aims to capitalize on the diverse healthcare landscapes and maximize its potential for growth and innovation.

What significant milestones has the company Legend Biotech achieved?

Legend Biotech Corp has achieved several significant milestones in its trajectory. Notably, the company successfully completed a Phase 1b/2 clinical trial for its lead product candidate, LCAR-B38M CAR-T cell therapy. This innovative therapy demonstrated compelling clinical responses in patients with relapsed or refractory multiple myeloma, leading to breakthrough status designation by the U.S. FDA. Subsequently, Legend Biotech Corp went on to initiate a global Phase 2 pivotal trial for LCAR-B38M. These achievements showcase the company's dedication to advancing groundbreaking treatments for patients, solidifying its position as a frontrunner in the biotech industry.

What is the history and background of the company Legend Biotech?

Legend Biotech Corp is a renowned biopharmaceutical company that focuses on developing cutting-edge cell therapies for patients with cancer. Founded in 2015 and headquartered in Somerset, New Jersey, Legend Biotech Corp is an affiliate of Genscript Biotech Corporation. The company primarily specializes in CAR-T cell therapies and has established a strong global presence. With a strong emphasis on research and development, Legend Biotech Corp has collaborated with numerous academic institutions and industry experts to advance the field of cell therapy. Leveraging its expertise and innovative approach, the company strives to improve the lives of patients worldwide by providing novel and effective treatments for various types of cancer.

Who are the main competitors of Legend Biotech in the market?

The main competitors of Legend Biotech Corp in the market include prominent biotechnology companies such as Gilead Sciences, Inc., Celgene Corporation, and bluebird bio, Inc.

In which industries is Legend Biotech primarily active?

Legend Biotech Corp is primarily active in the field of biotechnology.

What is the business model of Legend Biotech?

Legend Biotech Corp is a leading biopharmaceutical company that specializes in the discovery and development of innovative cell therapies. The company's business model revolves around leveraging its cutting-edge technologies and expertise in genetic engineering to develop personalized and off-the-shelf cell therapies for the treatment of various forms of cancer. By harnessing the power of the immune system, Legend Biotech aims to revolutionize the field of oncology and improve patient outcomes. With a focus on research and development, collaborations, and strategic partnerships, Legend Biotech is dedicated to advancing the future of cell-based immunotherapy and transforming the way cancer is treated.

What is the P/E ratio of Legend Biotech 2024?

The Legend Biotech P/E ratio is -34.81.

What is the P/S ratio of Legend Biotech 2024?

The Legend Biotech P/S ratio is 23.34.

What is the Quality Investing of Legend Biotech?

The Quality Investing for Legend Biotech is 4/10.

What is the revenue of Legend Biotech 2024?

The expected Legend Biotech revenue is 598.91 M USD.

How high is the profit of Legend Biotech 2024?

The expected Legend Biotech profit is -401.48 M USD.

What is the business model of Legend Biotech

Legend Biotech Corp is an innovative biotechnology company specializing in the development of cell therapies for cancer and autoimmune diseases. The company was founded in 2015 and is headquartered in Somerset, New Jersey. Its business model focuses on discovering and developing therapies for difficult-to-treat diseases, utilizing expertise in gene and cell therapy as well as a proprietary platform for designing, manufacturing, and optimizing therapy products. The company has two main divisions: cancer therapy and autoimmune therapy. In cancer therapy, Legend Biotech Corp focuses on developing immunotherapies that activate the body's immune system to destroy cancer cells, with a promising pipeline of cell therapies for various types of cancer. In autoimmune therapy, the company is developing cell therapies for diseases such as rheumatoid arthritis, multiple sclerosis, and systemic lupus erythematosus, using a similar approach to the cancer therapy division. The company's product portfolio includes several products in various stages of clinical development, including CAR-T cell therapies for the treatment of Hodgkin's lymphoma and multiple myeloma. Legend Biotech Corp also places a strong emphasis on partnerships and collaborations, working closely with research institutions, universities, and other biotechnology companies to optimize its technology and therapy platforms and develop new products. Overall, the company's business model is characterized by innovative research and development, a focus on discovering new therapies, and close collaboration with partners and other industry stakeholders. The company is well positioned to develop and bring successful cell therapies for cancer and autoimmune diseases to the market.

What is the Legend Biotech dividend?

Legend Biotech pays a dividend of 0 USD distributed over payouts per year.

How often does Legend Biotech pay dividends?

The dividend cannot currently be calculated for Legend Biotech or the company does not pay out a dividend.

What is the Legend Biotech ISIN?

The ISIN of Legend Biotech is US52490G1022.

What is the Legend Biotech WKN?

The WKN of Legend Biotech is A2P5AH.

What is the Legend Biotech ticker?

The ticker of Legend Biotech is LEGN.

How much dividend does Legend Biotech pay?

Over the past 12 months, Legend Biotech paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Legend Biotech is expected to pay a dividend of 0 USD.

What is the dividend yield of Legend Biotech?

The current dividend yield of Legend Biotech is .

When does Legend Biotech pay dividends?

Legend Biotech pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Legend Biotech?

Legend Biotech paid dividends every year for the past 0 years.

What is the dividend of Legend Biotech?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Legend Biotech located?

Legend Biotech is assigned to the 'Health' sector.

Wann musste ich die Aktien von Legend Biotech kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Legend Biotech from 11/9/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 11/9/2024.

When did Legend Biotech pay the last dividend?

The last dividend was paid out on 11/9/2024.

What was the dividend of Legend Biotech in the year 2023?

In the year 2023, Legend Biotech distributed 0 USD as dividends.

In which currency does Legend Biotech pay out the dividend?

The dividends of Legend Biotech are distributed in USD.

All fundamentals about Legend Biotech

Our stock analysis for Legend Biotech Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Legend Biotech Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.